Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $3.64

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) gapped up prior to trading on Thursday . The stock had previously closed at $3.64, but opened at $3.81. Ginkgo Bioworks shares last traded at $3.76, with a volume of 142,480 shares traded.

Several research analysts have commented on DNA shares. Cowen started coverage on shares of Ginkgo Bioworks in a report on Wednesday, March 2nd. They issued an “outperform” rating and a $12.00 price objective for the company. Zacks Investment Research lowered shares of Ginkgo Bioworks from a “buy” rating to a “hold” rating in a report on Monday, April 4th. The Goldman Sachs Group initiated coverage on shares of Ginkgo Bioworks in a report on Wednesday, February 23rd. They issued a “neutral” rating and a $7.00 price objective for the company. Bank of America restated a “neutral” rating and set a $6.00 target price on shares of Ginkgo Bioworks in a report on Tuesday, February 1st. Finally, Raymond James decreased their price target on shares of Ginkgo Bioworks from $14.50 to $11.50 and set an “outperform” rating for the company in a research note on Tuesday, April 5th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $8.82.

The company has a debt-to-equity ratio of 0.01, a current ratio of 12.79 and a quick ratio of 12.76. The business has a 50-day moving average price of $3.80 and a 200 day moving average price of $7.79.

Ginkgo Bioworks (NYSE:DNAGet Rating) last issued its quarterly earnings results on Monday, March 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.95). On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.13 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Equitec Proprietary Markets LLC grew its holdings in shares of Ginkgo Bioworks by 1,992.3% during the first quarter. Equitec Proprietary Markets LLC now owns 1,662,456 shares of the company’s stock valued at $6,700,000 after buying an additional 1,583,000 shares during the last quarter. 180 Wealth Advisors LLC grew its holdings in shares of Ginkgo Bioworks by 108.4% during the first quarter. 180 Wealth Advisors LLC now owns 26,361 shares of the company’s stock valued at $101,000 after buying an additional 13,714 shares during the last quarter. Transcend Capital Advisors LLC purchased a new stake in shares of Ginkgo Bioworks during the first quarter valued at approximately $176,000. Endurance Wealth Management Inc. grew its holdings in shares of Ginkgo Bioworks by 100.0% during the first quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company’s stock valued at $40,000 after buying an additional 5,000 shares during the last quarter. Finally, Foundations Investment Advisors LLC grew its holdings in shares of Ginkgo Bioworks by 70.1% during the first quarter. Foundations Investment Advisors LLC now owns 164,846 shares of the company’s stock valued at $633,000 after buying an additional 67,909 shares during the last quarter.

Ginkgo Bioworks Company Profile (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Stories

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.